Merck (MRK) Said to Be Unidentified Suitor for Acceleron Pharma (XLRN), Not Bristol-Myers Squibb (BMY) - Report

September 27, 2021 6:02 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Merck & Co., Inc. (NYSE: MRK) is nearing a deal to acquire Acceleron Pharma Inc. (NASDAQ: XLRN), in an agreement that could be completed as soon as this week, The Wall Street Journal reported citing people familiar with the matter.

The agreement, which will bolster Merck & Co’s rare-disease business, would be one of its biggest deals, should it come together.

Shares of Acceleron Pharma rose 6.7% intra-day Monday after a Bloomberg report after the close Friday that the company was for sale to a large unidentified pharmaceutical company.

Before the Journal story, Bristol-Myers Squibb (NYSE: BMY), which already owns a large stake in the company, was thought to be that suitor. It is unclear if both companies are involved in bidding for Acceleron.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot M&A, Mergers and Acquisitions, Rumors

Related Entities

Definitive Agreement